|
|
|
| Expression and clinical significance of IL-7 in peripheral blood and intestines tissue of the colorectal disorders |
| TU Qiang1,2, PENG Qi-song2, JIN Jie1 |
| (1. School of Medicine, Jiangsu University, Zhenjiang Jiangsu 212013; 2. Department of Clinical Laboratory, Jiangning Hospital of Nanjing, Nanjing Jiangsu 211100, China) |
|
|
|
|
Abstract Objective： To investigate the expression of IL-7 in peripheral blood and intestinal tissues and its clinical significance. Methods：The expression level of IL-7 in peripheral blood of 20 patients with ulcerative colitis and 27 patients with colorectal cancer were detected by ELISA.Thirteen healthy volunteers were used as controls.The immunohistochemical method was also used to detect the intestinal tissue expression of IL-7 in 20 cases of ulcerative colitis and 27 cases of colorectal cancer. The corresponding adjacent normal tissues were collected as controls. Results：The level of IL-7 in peripheral blood of patients with colorectal cancer is (2.98±0.93) ng/L, which is significantly lower than that of patients with enteritis \[(4.72±0.69) ng/L,P<0.01\] and healthy controls［（5.64±0.24）ng/L，P＜0.01］. The expression of IL-7 was strongly positive in the intestinal carcinoma tissue of 14 colorectal cancer patients(51.85%) and was weakly positive only in the carcinoma adjacent tissues of corresponding 5 colorectal cancer patients (18.52%) and in the colorectal mucosa of 5 patients with enteritis(25.00%). The expression of IL-7 in colorectal cancer tissues was significantly higher than that in its adjacent tissues(χ2=8.333,P<0.05), and also significantly higher than that in intestinal mucosa tissue of ulcerative colitis(χ2=4.454,P<0.05). Conclusion：The expression of IL-7 in peripheral blood and intestinal tissue can be used as a candidate diagnostic index for clinical intestinal diseases.
|
|
Received: 09 September 2016
|
|
|
|
| ［1］Soerjomataram I, LortetTieulent J, Parkin MD, et al. Global burden of cancer in 2008: a systematic analysis of disability adjusted lifeyears in 12 world regions\[J\]. Lancet,2012,380(9856):1840-1850.［2］Kelsen DP.胃肠肿瘤学:原理与实践\[M\].2版.梁寒,译.天津:天津科技翻译出版有限公司,2012.［3］Pellegrini M, Calzascia T, Toe JG, et al. IL7 engages multiple mechanisms to overcome chronic viral infection and limitorgan pathology\[J\]. Cell, 2011, 144(4):601-613.［4］Unsinger J, McGlynn M, Kasten KR, et al. IL7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis\[J\].J Immunol,2010,184(7):3768-3779.［5］Mackall CL, Fry TJ, Gress RE. Harnessing the biology of IL7 for therapeutic application\[J\].Nat Rev Immunol,2011,11(5):330-342.［6］Sportès C, Babb RR, Krumlauf MC, et al. Phase Ⅰ study of recombinant human interleukin7 administration in subjects with refractory malignancy\[J\].Clin Cancer Res, 2010,16(2):727-735.［7］Foss HD,Hummel M,Gottstein S,et al.Frequent expression of IL7 gene transcripts in tumor cells of classical Hodgkins disease\[J\].Am J Pathol,1995,146(1):33-39.［8］Jacobs SR,Michalek RD,Rathmell JC, et al.IL7 is essential for homeostatic control of T cell metabolism in vivo\[J\].J Immunol,2010,184(7):3461-3469.［9］Guimond M,Veenstra RG,Grindler DJ,et.al.Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells\[J\]. Nat Immunol,2009,10(2):149-157. |
|
|
|
2016, Vol. 26 
